Great to see Longeveron Inc's progress advancing stem cell therapy for two devastating diseases, HLHS and Alzheimer's disease, as they reported in their Q3 2024 financial results and business update. CEO Wa'el Hashad commented, "The ELPIS II clinical trial in HLHS is a key priority and we are delighted to have achieved more than 80% enrollment. Our recent positive Type C meeting with the FDA confirmed ELPIS II is pivotal and, if positive, acceptable for Biological License Application (BLA) submission for full traditional approval.?Similarly, we are excited by the strength of the CLEAR MIND Phase 2a clinical data in mild Alzheimer’s disease and the interest it is garnering with the data selected as a featured research oral presentation at the 2024 Alzheimer's Association International Conference (AAIC) in July, and additional data selected for Late Breaking poster presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24). We believe stem cell therapy has the potential to become a mainstream treatment for many conditions with significant unmet medical needs and that Longeveron is well positioned to be a leader in stem cell research and potential commercialization.” https://lnkd.in/gHt5zfpC #stemcelltherapy #HLHS #alzheimersdisease #EndALZ
Investor Relations Advisory Solutions
公共关系和沟通服务
Denver，Colorado 104 位关注者
Investor relations/corporate communications solutions for public and private companies from senior level experts.
关于我们
Investor Relations Advisory Solutions is a strategic advisory firm specializing in investor relations and corporate communications. We partner with clients to effectively communicate their business and achievements to the global investment community. Our fundamental goals in supporting clients are: - Maximize the impact of clients' investor relations initiatives while optimizing management's time and effort; and - Maximize corporate valuation to support continued growth, financings and M&A. We provide tailored, results driven investor relations and communications solutions and counsel, executed by experienced, senior level practitioners, each of whom has previously headed the in-house investor relations and corporate communications function at publicly listed companies.
- 所属行业
- 公共关系和沟通服务
- 规模
- 2-10 人
- 总部
- Denver，Colorado
- 类型
- 私人持股
- 创立
- 2011
- 领域
- Investor Relations、Corporate Communications、Financial Relations、Financing Support、Social Media、Media Relations、Direct Exchange Listings、Exchange Uplisting、IPO、Pre-IPO和Shareholder Communications
地点
Investor Relations Advisory Solutions员工
动态
-
Investor Relations Advisory Solutions转发了
Longeveron is scheduled to report third quarter 2024 financial results tomorrow, Tuesday, November 12th, after the close of U.S. markets. Our CEO?Wa’el Hashad, CFO Lisa Locklear, Founder and CSO Joshua Hare and CMO Dr. Nataliya Agafonova will host a conference call to discuss the results and provide a business update at 4:30pm ET.??For webcast access details, please visit?https://lnkd.in/de4zh-Y9
-
Great to see initial positive data from ELPIS I extend out 5 years! 100% transplant-free survival at 5 years is encouraging. #HLHS is such a devastating condition for the infants and their families. ELPIS II is currently enrolling to evaluate stem cell therapy Lomecel-B as a potential adjunct treatment for HLHS. Longeveron Inc continues to deliver positive clinical data for stem cell therapy Lomecel-B across multiple indications, including HLHS and #Alzheimers. Congratulations to the entire Longeveron team.
Positive long-term (5yr) transplant-free survival data from a multi-year follow-on study to the ELPIS I Phase 1 clinical trial evaluating stem cell therapy Lomecel-BTM?in rare pediatric disease HLHS?were featured in an oral presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting yesterday (Oct 27th).?? https://lnkd.in/gs5PhRsm Key findings include: ? 5-year post-Glenn procedure Kaplan-Meier survival was 100% in patients treated with Lomecel-B? in ELPIS I, with none requiring heart transplant. This compared to 83% (95% CI= [77.4, 89.3]) transplant-free survival in the SVR trial through 5 years post-Glenn surgery, and a 5.2% (95% CI= [2.0, 8.3]) heart transplantation rate. ? No Major Adverse Cardiovascular Events (MACE) were reported during the study. ? No Lomecel-BTM?related safety issues were reported. ? These findings support the use of Lomecel-BTM?as a potential adjunct to HLHS reconstruction surgery to improve transplant-free survival. #HLHS #celltherapy #stemcells #regenerativemedicine
-
Investor Relations Advisory Solutions转发了
Congratulations to Longeveron Inc on a successful quarter making progress towards hopefully having an impact for patients with #Alzheimer's disease and #HLHS. The Company's development programs for these diseases have received five U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program -?Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. Best wishes for continued success with the clinical development of Lomecel-B.
Today, we provided a business update and reported financial results through the first half of 2024. ·???????Positive data from the Phase 2a clinical trial (CLEAR MIND ) evaluating Lomecel-BTM?in Alzheimer’s disease presented in Featured Research Oral Presentation at Alzheimer’s Association International Conference? (AAIC) ·???????U.S. FDA granted Lomecel-B? both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease ·???????Phase 2b clinical trial (ELPIS II) evaluating Lomecel-BTM?in rare pediatric disease HLHS has achieved 70% enrollment with completion of enrollment targeted for the end of 2024 ·???????Strengthened Board of Directors with election of 3 experienced industry veterans at Annual Meeting ·???????Focused expenditure management reduced first half Total Operating Expenses 22% year-over-year ·???????Financing transaction and warrant exercises in July raised gross proceeds of $15.3 million to fund continued clinical development, and current cash and cash equivalents are expected to be sufficient to fund Company?through the fourth quarter of 2025 Read the full press release:?https://lnkd.in/g4QWJMgW
-
-
Congratulations to Longeveron Inc on a successful quarter making progress towards hopefully having an impact for patients with #Alzheimer's disease and #HLHS. The Company's development programs for these diseases have received five U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program -?Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. Best wishes for continued success with the clinical development of Lomecel-B.
Today, we provided a business update and reported financial results through the first half of 2024. ·???????Positive data from the Phase 2a clinical trial (CLEAR MIND ) evaluating Lomecel-BTM?in Alzheimer’s disease presented in Featured Research Oral Presentation at Alzheimer’s Association International Conference? (AAIC) ·???????U.S. FDA granted Lomecel-B? both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease ·???????Phase 2b clinical trial (ELPIS II) evaluating Lomecel-BTM?in rare pediatric disease HLHS has achieved 70% enrollment with completion of enrollment targeted for the end of 2024 ·???????Strengthened Board of Directors with election of 3 experienced industry veterans at Annual Meeting ·???????Focused expenditure management reduced first half Total Operating Expenses 22% year-over-year ·???????Financing transaction and warrant exercises in July raised gross proceeds of $15.3 million to fund continued clinical development, and current cash and cash equivalents are expected to be sufficient to fund Company?through the fourth quarter of 2025 Read the full press release:?https://lnkd.in/g4QWJMgW
-
-
Looking forward to the Longeveron (LGVN) Phase 2a clinical data in Alzheimer's data selected for a Featured Research oral presentation this Sunday (July 28th) at the Alzheimer’s Association International Conference? (AAIC). Such important work in a devastating disease. #EndALZ #Alzheimers #Longeveron #celltherapy https://lnkd.in/gTiBNCZc
Phase 2a Lomecel-B(TM)data in mild Alzheimer’s Disease selected for Featured Research Session oral presentation and poster presentation at the Alzheimer’s Association International Conference? (AAIC) starting this weekend. Oral Presentation: Date:?Sunday, July 28, 2024 Time:?4:15 pm – 5:45 pm EDT Session:?Featured Research Session, 1-32-FRS-B Title:?Results from a Phase 2a Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Lomecel-B(TM)?in Mild Alzheimer’s Disease Dementia
-